

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062
919-862-2200
Fax: 919-862-2260

RECEIVED
CENTRAL FAX CENTER

JAN 19 2006

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

Date:

January 19, 2006

Recipient:

Shaojia A. Jiang

Company:

USPTO

Fax Number:

571 273 8300

Voice Number:**Sender:**

Edward R. Ergenzinger, Jr.

Message:

Appl. No.: 10/799,490

Confirmation No.: 8365

Applicant(s): Thor

Filed: March 12, 2004

Art Unit: 1614

Examiner: Jiang, Shaojia A.

Title: METHODS OF USING COMPOUNDS WITH COMBINED 5-HT1A
ANTAGONIST AND SSRI ACTIVITIES AS-NEEDED TO TREAT SEXUAL
DYSFUNCTION (AS AMENDED)

Docket No.: 046562/274661

Customer No.: 00826

Number of Pages: (including cover page)

4

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT.

USER CODE: ERGEG
CLIENT/MATTER: 046562/274661

REQUESTED BY: Lynda, 2233
OPERATOR:

JAN -19' 06 (THU) 16:33

ALSTON & BIRD

TEL:9198622260

P. 002

RECEIVED
CENTRAL FAX CENTER

JAN 19 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/799,490

Confirmation No.: 8365

Applicant(s): Thor

Filed: March 12, 2004

Art Unit: 1614

Examiner: Jiang, Shaojia A.

Title: METHODS OF USING COMPOUNDS WITH COMBINED 5-HT1A
ANTAGONIST AND SSRI ACTIVITIES AS-NEEDED TO TREAT SEXUAL
DYSFUNCTION (AS AMENDED)

Docket No.: 046562/274661

Customer No.: 00826

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT
37 CFR § 1.115

Sir:

Please enter this Preliminary Amendment and amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

| of 3

RTA01/2106778v1